This video describes pivotal 1- and 2-year results from the ATLAS study (including study design), presented at this year’s ARVO congress, held in Seattle, US (Wednesday 04 May 2016, 12:15-12:30 PM, Program Number 4721). A total of 40 participants were enrolled for this multicentre, prospective, open label study, and treated with aflibercept for neovascular age-related macular degeneration using a treat-and-extend regimen. DeCroos et al. from the Wills Eye Institute reported a median best corrected visual acuity improvement of 11 early treatment diabetic retinopathy study (ETDRS) letters (P<0.001) at Year 1, with a slight decrease to 8 ETDRS letters at Year 2. No ocular or related systemic adverse events were observed.
ATLAS study
Other Perspective
Treat and Extend – Practical guide
Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi
Biosimilars, a new frontier?
Biosimilars entering the scene of intravitreal injections
Anti-VEGF therapies for AMD: where are we now?
Where are we now with the spread of these therapies for AMD to prevent blindness?
Defining Nonadherence and Nonpersistence to Anti-VEGF Therapies in nAMD
The nAMD Barometer Leadership Coalition published a definition for nonadherence and nonpersistence
Related Articles
